Antibacterial and antibiofilm activities of selenium nanoparticles-antibiotic conjugates against anti-multidrug-resistant bacteria
Dalal M. Ridha,Mohammed J. Al-Awdy,Afrah J. Abd Al-Zwaid,Asim A. Balakit,Hussein O.M. Al-Dahmoshi,Mohammad Hayal Alotaibi,Gamal A. El-Hiti
DOI: https://doi.org/10.1016/j.ijpharm.2024.124214
IF: 6.51
2024-05-10
International Journal of Pharmaceutics
Abstract:The crucial demand to overcome the issue of multidrug resistance is required to refine the performance of antibiotics. Such a process can be achieved by fastening them to compatible nanoparticles to obtain effective pharmaceuticals at a low concentration. Thus, selenium nanoparticles (Se NPs) are considered biocompatible agents that are applied to prevent infections resulting from bacterial resistance to multi-antibiotics. The current evaluated the effectiveness of Se NPs and their conjugates with antibiotics such as amikacin (AK), levofloxacin (LEV), and piperacillin (PIP) against Pseudomonas aeruginosa ( P. aeruginosa ). In addition, the study determined the antibacterial and antibiofilm properties of Se NPs and their conjugates with LEV against urinary tract pathogens such as Staphylococcus aureus ( S. aureus ), Enterococcus faecalis ( E. faecalis ), P. aeruginosa , and Escherichia coli ( E. coli ). The result of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) for eight isolates of P. aeruginosa revealed that the conjugation of Se NPs with AK, LEV, and PIP resulted in a reduction in the concentration of antibiotic-conjugated Se NPs. The concentration was found to be about 10–20 times lower than that of bare antibiotics. The MIC of the Se NPs with LEV (i.e., Se NPs:LEV) for S. aureus , E. faecalis , P. aeruginosa , and E. coli was found to be 1.4:0.5, 0.7:0.25, 22:8, and 11:4 μg/mL, respectively. The results of the half-maximal inhibitory concentration (IC 50 ) demonstrated that Se NPs:LEV conjugate have inhibited 50 % of the mature biofilms of S. aureus , E. faecalis , P. aeruginosa , and E. coli at a concentration of 27.5 ± 10.5, 18.8 ± 3.1, 40.6 ± 10.7, and 21.6 ± 3.3 μg/mL, respectively compared to the control. It has been suggested that the antibiotic-conjugated Se NPs have great potential for biomedical applications. The conjugation of Se NPs with AK, LEV, and PIP increases the antibacterial potency against resistant pathogens at a low concentration.
pharmacology & pharmacy